JPRN-UMIN000019098已完成未知
Analysis of efficacy of the SGLT2 inhibitor alone or in combination with the DPP-4 inhibitor on urinary and plasma DPP-4 activities in obese patients with type 2 diabetes. - Analysis of efficacy of the SGLT2 inhibitor alone or in combination with the DPP-4 inhibitor on urinary and plasma DPP-4 activities in obese patients with type 2 diabetes.
Graduate School of Medicine, University of the Ryukyus0 个研究点目标入组 12 人开始时间: 2015年9月29日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
Canagliflozin(Cana) 12-week administration improved HbA1c, plasma DPP4 activity, BW, BMI, VFM, abdominal circumference, fasting serum glucose, fasting serum insulin, serum C-peptide, and ALT. Among the 12 cases, HbA1c, AST, and ALT were decreased and heart rate was increased in the group (12W vs.24W) that was combined with Teneligliptin(Tene) in 9 cases.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Under treatment with SGLT2 inhibitor,DPP-4 inhibitor, insulin, or GLP-1 analog 2) Severe ketosis, diabetic coma, or diabetic precoma within the past six months 3) Type 1 diabetes 4) Pituitary gland dysfunction, adrenal gland dysfunction 5) Severe infectious diseases, pre or post surgery, and serious trauma 6) Pregnant women, women suspected of being pregnant, or lactating women 7) Severe renal function disorder (eGFR < 45) 8) Severe liver function disorder 9) History of malignant tumor 10) Cardiac arrest (class of IV in NYHA) 11) Self-contained device such as pacemakers 12) Wearable devices such as Holter electrocardiographs 13) Implantable metallic medical devices
研究者
相似试验
已完成
Unknown
Prospective observational study of SGLT2 inhibitor, ipragliflozin in patients with type 2 diabetesType 2 DiabetesJPRN-jRCT1090220182General Incorporated Association Nagoya Medical Association600
撤回
4 期
The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 InsulinDiabetes, ObesityNCT02597309Joslin Diabetes Center
已完成
4 期
Mechanisms of Weight Loss With SGLT2 InhibitionOverweightObesityType 2 DiabetesNCT02360774Beth Israel Deaconess Medical Center30
已完成
不适用
The study of effects of Canagliflozin ON T2DM patients' glycemic value Reduction and On Lowering dosage of insulin therapyType 2 diabetesJPRN-UMIN000018085niversity of Occupational and Environmental Health58
已完成
不适用
Effect of SGLT2 inhibitor, canagliflozin, for the size of lipid particlesType 2 diabetesJPRN-UMIN000020027Tokyo Medical and Dental University Department of Medical Genetics / Gerontorgy30